{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"327.861","value":"431.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"}],"units":"Participants"}],"title":"Cycle 1 Day 1: End of infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"107.228","value":"89.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"}],"units":"Participants"}],"title":"Cycle 2 (Week 4): Pre-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.561","value":"159.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"}],"units":"Participants"}],"title":"Cycle 5 (Week 16): Pre-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.422","value":"178.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"title":"Cycle 26 (Week 100): Pre-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.026","value":"44.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"}],"units":"Participants"}],"title":"Month 3 follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"}],"units":"Participants"}],"description":"Blood samples were collected to determine the concentration of durvalumab.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received durvalumab monotherapy (1500 mg for participants \\>30 kg in weight and a weight-based dosing equivalent to 20 mg/kg for participants \\<=30 kg in weight) via IV infusion once q4w, until clinical/RECIST 1.1-defined radiological progression, intolerable toxicity, or for a maximum of 24 months, whichever occurred first.","id":"OG000","title":"Durvalumab"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK) population included all participants who received at least 1 dose of study drug per the protocol for whom any post-dose data were available and who did not violate or deviate from the protocol in ways that would have significantly affected the PK analyses. Only those participants with data collected at specified timepoints are reported.","reportingStatus":"POSTED","timeFrame":"End of infusion on Cycle 1 Day 1, pre-infusion on Cycle 2 (Week 4), Cycle 5 (Week 16) and Cycle 26 (Week 100) and Month 3 post last dose of study treatment (Week 119) (each treatment cycle is 28 days)","title":"Durvalumab: Serum Concentration of Durvalumab","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (mcg/mL)"}